NY-ANTLER
13.10.2021 15:07:12 CEST | Business Wire | Press release
Global venture capital firm Antler has announced that it has closed over $300m to date, allowing it an opportunity to provide continued support to its companies in subsequent funding rounds. Investors in the funds include Schroders, Vækstfonden, and Phoenix Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211013005689/en/
Antler is on a mission to fundamentally improve the world by enabling and investing in the world's most exceptional people. The primary focus of the firm will remain investing at the pre-seed stage, with the firm now also having the ability to offer its portfolio companies follow-on capital as they grow and scale, up to Series C.
Magnus Grimeland, CEO and Founder of Antler, said “We continue to provide support for our founders from the earliest stages, and are thrilled to be able to continue investing in them as they grow. We look forward to backing even more entrepreneurs that are redefining industries in the future.”
Antler is continually developing and expanding its senior team, and its global presence. To this end, Antler has recruited new partners Naman Budhdeo, Erik Jonsson, Jiho Kang, and Subir Lohani to lead its new Canada, Vietnam, Korea, and Indonesia teams respectively.
Teddy Himler from SoftBank also joins as a Partner of the later-stage investment team.
Antler has invested in over 350 companies globally across over 30 different industries since 2018. Of these companies, 40% have at least one female co-founder, with 70 nationalities represented.
Antler continues to invest in its portfolio companies as they scale. The firm has a global network of over 600 expert advisors, and an online platform of resources, tools and supports its portfolio companies with introductions to global investors, hands-on assistance with new market entry, and access to a global network of expert advisors.
In providing continued support and investment, Antler confirms its position as a long-term partner for exceptional entrepreneurs -- from the outset of their journey, to the later stages as they scale.
Antler also intends to now invest in a number of companies from outside of its portfolio at seed and Series A stages. Antler has put together a team to oversee on-going investments, led by Antler partners: Martell Hardenberg, Co-Founder of Lazada; Teddy Himler, formerly of SoftBank; Stefan Jung, previously Managing Partner at Venturra Capital; and Navi Singh, a Researcher at MIT's Department of Mechanical Engineering.
This on-going evolution is built on what we believe to be a strong structural advantage in deal flow sourcing from regionally focused early-stage investments across 15 countries in 5 continents, including: Australia (Melbourne and Sydney), Canada (Toronto), Denmark (Copenhagen), Germany (Berlin), India (Bangalore), Indonesia (Jakarta), Kenya (Nairobi), Norway (Oslo), Sweden (Stockholm), Singapore, South Korea (Seoul), The Netherlands (Amsterdam), The UK (London), US (Austin and New York), and Vietnam (Ho Chi Minh).
Lieven Debruyne, Global Head of Distribution at Schroders said, “As a longstanding partner and investor in Antler, we are delighted to continue our investment in Antler. It is a unique opportunity to gain exposure to a global growth portfolio of innovative technology companies, and to ensure a steady stream of capital is being invested in companies that will define how we all live and work in the future”
Lars Nordal Jensen, Senior Director at Vækstfonden said, “We are thrilled to continue our commitment to Antler. We have previously invested in Antler, and have been delighted with the firm’s overwhelmingly positive contribution to the technology ecosystem since their market entry. In Vaekstfonden we want to help drive innovation and new technology, and therefore we are very pleased to see Antler continue its commitment to supporting innovative founders throughout their journey”
THIS PRESS RELEASE IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. NO OFFERING OF INTERESTS OF THE FUNDS REFERRED TO ABOVE HAS BEEN OR WILL BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER ANY OTHER U.S. FEDERAL AND STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED IN THE UNITED STATES OR TO U.S. INVESTORS, UNLESS THEY ARE REGISTERED, OR EXEMPT FROM, OR NOT SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT.
-ENDS-
About Antler
Antler is a global early-stage venture capital firm that invests in the defining technology companies of tomorrow. The firm has offices globally across most major entrepreneurial hubs, including in London, Berlin, Stockholm, New York, Singapore and Sydney.
Founded in Singapore in 2017, Antler is on a mission to fundamentally improve the world by enabling and investing in the world's most exceptional people, by building complementary co-founder teams, supporting the teams with deep business model validation and providing a global platform for scaling. To date, Antler has invested in over 350 companies globally across 30 different industries. Of these companies, 40% have at least one female co-founder, and the founders represent 70 nationalities. Antler’s current portfolio of startups includes: HomeBase , Reebelo , Qashier , Volopay , Pathzero , Marco Financial , Xanpool , PowerX , and Xailient .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005689/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
